ethyl 1-(4-chlorophenyl)-1H-1,2,4-triazole-3-carboxylate | 150112-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 1-(4-chlorophenyl)-1H-1,2,4-triazole-3-carboxylate
• 英文别名: Ethyl 1-(4-chlorophenyl)-1,2,4-triazole-3-carboxylate；ethyl 1-(4-chlorophenyl)-1,2,4-triazole-3-carboxylate
• CAS: 150112-44-0
• 化学式: C₁₁H₁₀ClN₃O₂
• 分子量: 251.672
• InChiKey: OSYOVOMYLNFHQG-UHFFFAOYSA-N

物化性质

• 熔点：
  135-136 °C(Solv: ethanol (64-17-5))
• 沸点：
  398.3±44.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 1-(4-chlorophenyl)-1H-1,2,4-triazole-3-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以82.5%的产率得到(1-(4-chlorophenyl)-1H-1,2,4-triazol-3-yl)methanol
  参考文献：
  名称：

  ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER

  摘要：

  公开号：

  EP3434674B1
• 作为产物：
  描述：

  4-氯苯胺盐酸盐 在 亚硝酸特丁酯 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 0.17h， 生成 ethyl 1-(4-chlorophenyl)-1H-1,2,4-triazole-3-carboxylate
  参考文献：
  名称：

  Flow synthesis of ethyl isocyanoacetate enabling the telescoped synthesis of 1,2,4-triazoles and pyrrolo-[1,2-c]pyrimidines

  摘要：

  基于1,2,4-三唑和吡啶并[1,2-c]嘧啶支架的重要杂环建筑块的高效流动合成已经实现。

  DOI：

  10.1039/c5ob00245a

文献信息

• [3 + 2] Cycloaddition of Isocyanides with Aryl Diazonium Salts: Catalyst-Dependent Regioselective Synthesis of 1,3- and 1,5-Disubstituted 1,2,4-Triazoles
  作者：Jian-Quan Liu、Xuanyu Shen、Yihan Wang、Xiang-Shan Wang、Xihe Bi

  DOI：10.1021/acs.orglett.8b03069

  日期：2018.11.2

  An unprecedented catalyst-dependent regioselective [3 + 2] cycloaddition of isocyanides with aryl diazonium salts is reported. 1,3-Disubstituted 1,2,4-triazoles were selectively obtained in high yield under Ag(I) catalysis, whereas 1,5-disubstituted 1,2,4-triazoles were formed by Cu(II) catalysis. These catalytic methodologies provide a controlled, modular, and facile access to 1,2,4-triazole scaffolds

  据报道，前所未有的催化剂依赖性异氰酸酯与芳基重氮盐的区域选择性[3 + 2]环加成反应。在Ag（I）催化下，高收率选择性地获得了1,3-二取代的1,2,4-三唑，而在Cu（II）催化下形成了1,5-二取代的1,2,4-三唑。这些催化方法学提供了高效，宽泛的底物范围和出色的官能团相容性的1,2,4-三唑支架的受控，模块化和便捷操作。
• CXCR7 ANTAGONISTS
  申请人：ChemoCentryx, Inc.

  公开号：US20140154179A1

  公开（公告）日：2014-06-05

  Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

  提供具有化学式I的化合物，或其药用可接受的盐、水合物或N-氧化物，并且这些化合物可用于与CXCR7结合，治疗部分或完全依赖于CXCR7活性的疾病。因此，根据本发明的进一步方面，提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。
• COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Haihe Pharmaceutical Co., Ltd.

  公开号：EP3434674A1

  公开（公告）日：2019-01-30

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• CXCR7 antagonists
  申请人：CHEMOCENTRYX, INC.

  公开号：US10287292B2

  公开（公告）日：2019-05-14

  Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

  具有式 I 的化合物、 本发明提供了具有式 I 的化合物或其药学上可接受的盐、水合物或 N-氧化物，可用于与 CXCR7 结合，治疗至少部分依赖于 CXCR7 活性的疾病。因此，本发明在进一步的方面提供了含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
• Compound having mutant IDH inhibitory activity, preparation method and use thereof
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.

  公开号：US10682352B2

  公开（公告）日：2020-06-16

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。